checkAd

     105  0 Kommentare Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company

    Regulatory News:

    Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) (Paris:ALMDT) announced today that the Company has been selected as preferred vendor by a Top 3 pharmaceutical company, adding another one of the largest global pharmaceutical companies to its client portfolio. Median Technologies is now preferred provider for two of the Top 3 pharma companies, based on oncology sales2.

    The Master Service Agreement (MSA) came after an in-depth selection process. The new client has one of the largest oncology pipelines in the world and presents one of the highest R&D to revenue ratios in the pharmaceutical industry3. Median will manage central image reads for late phase clinical trials in the client’s oncology pipeline. The MSA is a recognition of Median’s performance, quality, and competitiveness for imaging services worldwide.

    Fredrik Brag, CEO and Founder of Median Technologies said: Median’s’ iCRO services are best-in-class and recognized as such worldwide. The agreement will ensure stable future bookings and revenues growth for Median, while the Top 3 pharmaceutical company will benefit from improved operational execution using the best technology available in the market. Our recognized expertise in AI applied to medical images, has been a strong technology differentiator during the diverse phases of the negotiation; it represents a unique asset compared to the standard offering of our competitors as well as a major trigger for the acceleration of growth opportunities for our Company, in the era of precision medicine.”

    Nicolas Dano, COO & CCO iCRO, added: “The new preferred vendor agreement significantly strengthens our position in the United States. It is the result of our investments to deliver top-tier best-in-class imaging services, our commitment to achieving customer satisfaction, and the wealth of experience acquired in supporting sponsors with their regulatory filings. With the combination of our two offerings, iSee for central image reads, and Imaging Lab, iCRO’s unique AI-powered imaging offering, we cover a very wide and unique spectrum of imaging services for the pharma industry, from standard image reads to advanced imaging services using cutting edge AI-based technologies. We are proud to support the pharma industry in bringing the next generation of life-saving oncology drugs to market”.

    About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth stock exchange (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

    ______________________________

    1 Arjun Murthy – Top 15 biopharma companies by Oncology Sales in 2023
    2 Arjun Murthy – Top 15 biopharma companies by Oncology Sales in 2023
    3 Update: April 30, 2024: https://www.drugdiscoverytrends.com/top-pharma-companies-2023-rd-spend ...


    The Median Technologies Stock at the time of publication of the news with a raise of +3,59 % to 3,683EUR on Lang & Schwarz stock exchange (21. Mai 2024, 17:50 Uhr).


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Median Technologies, a World Leading Oncology Clinical Trial Imaging Services Provider, Becomes Preferred Vendor to Another Top 3 Pharmaceutical Company Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) (Paris:ALMDT) announced today that the Company has been selected as preferred vendor by a Top 3 pharmaceutical company, adding another one …

    Schreibe Deinen Kommentar

    Disclaimer